Innovation at Work

California

Total Direct and Indirect Economic Output of the Biopharmaceutical Sector

$260.9 billion

Total Employment Supported by the Biopharmaceutical Sector

895,813

A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

64%

Local Perspective: San Francisco, CA

Keith Yamamoto, Ph.D., Vice Chancellor for Science Policy and Strategy; Vice Dean for Research, School of Medicine, University of California, San Francisco

“We are witnessing an accelerated understanding of basic biological mechanisms that will lead to revolutionary new approaches to treat and prevent disease... Federal investment is the building blocks for long-term, transformative scientific discoveries.”

Californians who died from cardiovascular disease in 2015

61,289

Total NIH Award Funding (FY17)

$3,948 million

Research in the Golden State

The Salk Institute of Biological Sciences, University of California, San Diego (UCSD), and Nimbus Therapeutics, La Jolla, CA

In a National Institutes of Health (NIH) and Department of Defense (DoD)-funded collaboration between the Salk Institute, UCSD and Nimbus Therapeutics, researchers are working to develop a new treatment to inhibit cancer growth by interrupting an enzyme vital to lipid synthesis.

University of California, Davis, Davis, CA

The National Institutes of Health (NIH) is supporting neuroscientists at UC Davis working to discover microstructures related to attention in the brain. Better understanding of these brain systems could lead to improved treatments for attention disorders associated with psychiatric and neurological diseases, including attention deficit disorder, Parkinson’s and Alzheimer’s disease.

Genentech, Carlsbad, Carmichael, Fullerton, La Jolla, and Torrance, CA

Genentech is conducting phase III clinical trials to test the safety and efficacy of a new drug for multiple sclerosis (MS). The treatment is specifically intended for patients who have not experienced success with currently available therapies.

Sources: National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention (CDC), a Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in January 2017, ClinicalTrials.gov, The Salk Institute, National Science Foundation (NSF), UC Davis.